Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 2/02/24 → 1/02/26 |
Keywords
- Clinical trial
- MarkV-01
Clinical Trial Phase
- Phase I
A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
- Voskoboynik, Mark (Primary Chief Investigator (PCI))
- Brooks, Christine (Project Manager)
Project: Research